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BACKGROUND: Severe early and late radiation reaction to radiotherapy is extremely rare in breast cancer patients. Such a reaction
prompted an investigation into a 44-year-old mother (patient A-T213).
METHODS: A neurological examination was performed and blood lymphocytes and skin fibroblasts were assessed for radiosensitivity
chromosomally and by colony-forming assay. The ATM gene was sequenced and ATM mutations modelled by site-directed
mutagenesis. The ATM kinase activity was also assessed.
RESULTS: Patient A-T213 was normally ambulant with no ataxia and minimal other neurological features. T lymphocytes and skin
fibroblasts were unusually radiosensitive, although less sensitive than in classical ataxia telangiectasia (A-T). A lymphoblastoid cell line
and skin fibroblasts expressed ATM protein with some retained kinase activity. One missense ATM mutation c.8672G4A
(p.Gly2891Asp) and a c.1A4G substitution were identified. In the modelling system the p.Gly2891Asp mutant protein was
expressed and shown to have residual ATM kinase activity.
CONCLUSION: Patient A-T213 has a milder form of A-T with biallelic ATM mutations, which may have contributed to breast cancer
development, and certainly caused the severe radiation reaction. Ataxia telangiectasia should be investigated as a potential cause of
untoward severe early and late radiation reactions in breast cancer patients.
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Classical ataxia telangiectasia (A-T) is an early-onset progressive
neurodegenerative disorder caused by loss of function of the ATM
gene. Affected individuals are unable to walk a few steps
independently by early adulthood. This phenotype is most
frequently caused by biallelic null mutations in ATM that result
in the absence of ATM, a large 370kDa protein kinase (Taylor and
Byrd, 2005). ATM phosphorylates many target proteins such as
H2AX, MDC1, 53BP1, Nbs1, BRCA1, Chk2 and p53 that function to
regulate DNA DSB repair, chromatin remodelling, cell cycle
checkpoint activation, gene transcription, protein translation and
apoptosis (Lavin, 2008). In A-T, in the absence of ATM there is a
defective response to both intrinsically and extrinsically derived
cellular damage. In the brain, damaged cells may become incor-
porated into neuronal tissues, leading to neurodegeneration,
possibly as a result of failure of apoptosis (Shull et al, 2009).
Clinically, A-T is quite heterogeneous with some nonclassical
patients showing a much milder clinical progress as a consequence
of retaining expression of either some normal (McConville et al,
1996; Sutton et al, 2004) or mutant ATM protein (Stankovic et al,
1998; Carrillo et al, 2009; Verhagen et al, 2009) with residual ATM
kinase activity. Indeed, some A-T patients are not diagnosed until
adulthood (Sutton et al, 2004; Hiel et al, 2006).
Separate studies of A-T families (Olsen et al, 2001; Thompson
et al, 2005b) and of breast cancer families (Renwick et al, 2006)
have shown that carrying a single ATM mutation doubles the risk
of breast cancer. The presence of the missense mutation,
c.7271T4G (p.Val2424Gly), further increases the risk (Stankovic
et al, 1998; Bernstein et al, 2006). Also, A-T patients are at a
considerable increased risk of developing breast cancer; 45% by
the age of 50 years (Reiman et al, 2011) compared with B9% in
heterozygous carriers.
We report the occurrence of a mild form of A-T, with biallelic
ATM mutations in a 44-year-old breast cancer patient (A-T213)
who was investigated following a severe early and late reaction to
radiotherapy.
MATERIALS AND METHODS
Ethical approval
Ethical Approval was given by the National Research Ethics
Committee (REC Reference 07/H1210/155) and patient A-T213
gave informed consent.
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sCell culture
Epstein–Barr virus (EBV)-transformed lymphoblastoid cell lines
(LCLs) were established from A-T patient and control lymphocytes.
These LCLs were cultured in RPMI-1640 medium (Sigma-Aldrich,
Irvine, UK) supplemented with 10% fetal calf serum (FCS; PAA
Laboratories, Pasching, Austria). For transfected LCLs, 200mgml
–1
of hygromycin B (Invitrogen, Paisley, UK) was added to the media.
Colony-forming assays
Serial dilutions of TERT-immortalised fibroblasts were irradiated
with 1 to 5Gy of g-rays and seeded on to a lethally irradiated
(35Gy) feeder layer of normal fibroblasts (6 10
4 cells per 9.0cm
dish) in DMEM (Sigma-Aldrich) with 10% FCS. Cells were plated
in quadruplicate and incubated in 5% CO2 at 371C for 18–21 days
with medium changing. The medium was removed, colonies fixed
with formaldehyde and stained with 0.5% Methylene Blue (Fisher
Scientific, Loughborough, UK). The number of colonies on each
plate was counted and percentage survival calculated.
Modelling ATM mutations
The ATM cDNA (mRNA RefSeq NM_000051.3) representing the
complete open reading frame and coding sequence was cloned into
plasmid pcDNA4/HisMax (Invitrogen) to create pcDNA4/HisMax-
ATM. This was used as a template in subsequent mutagenesis
and cloning reactions. Site-directed mutagenesis was achieved
using the Quikchange II site-directed mutagenesis kit (Stratagene,
Amsterdam, The Netherlands). Both the 1A4G and the 8672G4A
ATM mutants were sequenced in full to verify the presence of the
desired sequence change and absence of any unwanted muta-
tion(s) acquired during the mutagenesis step. Full-length mutated
ATM constructs were transfected into ATM-null lymphoblastoid
cells (Barone et al, 2009). For detailed methods, see Supplementary
Information (Stewart et al, 2001).
Immunoblotting for ATM expression and ATM kinase
activity
To analyse ATM activity, cells were either mock irradiated or
exposed to 5Gy ionising radiation and harvested after 30min, and
nonirradiated cells were used for ATM expression analysis. Cell
pellets were resuspended in UTB buffer (9 M urea, 50mM Tris, pH
7.5, 150mM b-mercaptoethanol) and lysed on ice by sonication.
Lysate (50mg) was separated by SDS–polyacrylamide gel electro-
phoresis and the proteins transferred to nitrocellulose membrane
(Pierce, Rockford, IL, USA). Nitrocellulose strips were subjected to
immunoblotting and protein bands visualised using the enhanced
chemiluminescence (ECL) system (Amersham, Little Chalfont, UK)
and exposure to Hyperfilm MP autoradiography film (GE
Healthcare, Little Chalfont, UK). Antibodies used for immunoblot-
ting were ATM 11G12 (custom-made mouse monoclonal), pATM
Ser1981 #AF1655 (R&D Systems, Abingdon, UK), Smc1 #A300-
055A, pSmc1 Ser966 #A300-050A, KAP-1 #A300-275A, pKAP-1
Ser824 #A300-767A (Bethyl Laboratories, Universal Biologicals,
Cambridge, UK), Nbs1 #Ab398, pNbs1 Ser343 #Ab47272 (Abcam,
Cambridge, UK), pP53 Ser15 #9284, pChk2 Thr68 #2661, CREB
#48H2 (Cell Signaling Technology, NEB, Hitchin, UK), pCREB
Ser121 #NB100-410 (Novus Biologicals, Cambridge, UK), g-H2AX
(Millipore, Watford, UK), H2A (Millipore), BRCA1 Ser1423 (Bethyl
Laboratories), BRCA1 (Merck, Nottingham, UK) and Chk2 (gift
from Dr G Stewart).
In vitro ATM kinase assay
Patient-derived LCLs were either mock irradiated or exposed to
5Gy
137Cs g-rays and incubated for 30min at 371C. Cells were
harvested and lysed on ice for 30min in TGN lysis buffer (50mM
Tris, pH 7.5, 150mM sodium chloride, 10% glycerol, 50mM
b-glycerophosphate, 1% Tween-20, 0.2% nonidet P40 alternative,
1m M dithiothreitol, 0.1mM 4-(2-aminoethyl) benzenesulfonyl fluor-
ide, 1mM sodium orthovanadate, 10mM sodium fluoride, 10mgml
–1
aprotinin, 5mgml
–1 leupeptin hydrochloride and 2mgml
–1
pepstatin A). The ATM kinase was immunoprecipitated from 1mg
of each whole-cell lysate using 10mg anti-ATM antiserum (Ab-3,
Merck Chemicals, Darmstadt, Germany) for 2h at 41C. The ATM
immunoprecipitates were pulled down using 30ml of Protein A
agarose beads (Sigma-Aldrich) for 2h at 41C. Bead complexes were
washed twice in TGN buffer, once in TGN buffer plus 0.5 M lithium
chloride and twice in ATM kinase buffer (20mM HEPES, pH 7.5,
10mM MgCl2,1 0 m M MnCl2,5 0 m M b-glycerophosphate, 1mM
dithiothreitol, 0.1mM sodium orthovanadate, 1mM sodium fluoride,
0.1 M 4-(2-aminoethyl) benzenesulfonyl fluoride, 10mgml
–1 aproti-
nin, 5mgml
–1 leupeptin hydrochloride and 2mgml
–1 pepstatin A)
to remove residual detergent.
Each immunoprecipitate was resuspended in kinase buffer
supplemented with 20mM ATP (Sigma-Aldrich), 5mg of purified
GST-p531 72 substrate and 10mCi
32P[g-ATP] (New England
Nuclear, Boston MA, USA) and incubated at 301C for 6min.
Reactions were terminated by the addition of SDS sample buffer
(250mM Tris, pH 6.8, 8% (w/v) sodium dodecylsulphate, 10% (v/v)
glycerol, 0.01% (w/v) bromophenol blue, 400mM dithiothreitol),
incubated at 1001C for 5min and proteins were fractionated on
6%/8% biphasic SDS–polyacrylamide gels. The lower gel phase
was dried at 801C for 1h and exposed to autoradiographic film to
visualise phosphorylation of the GST-p531 72 substrate. The
protein in the upper gel phase was transferred to nitrocellulose
membrane (Pierce) and immunoblotted for the presence of
immunoprecipitated ATM protein using anti-ATM antiserum
(custom-made mouse monoclonal 11G12). Proteins were visua-
lised as above.
RESULTS
Clinical and neurological features
Patient A-T213, a 44-year-old working mother, developed a lump
in her right breast and was diagnosed with breast cancer (T2 G2,
two nodes positive, ER-positive carcinoma of right breast).
Treatment consisted of a lumpectomy followed by adjuvant
chemotherapy (FEC) and radiotherapy (standard protocol deliver-
ing 40Gy in fifteen fractions over 3 weeks). Post treatment, an
acute radiation reaction at the severe end of the normal spectrum
developed, followed by a late reaction manifest as shrinkage and
deformation of the breast (Figure 1). The patient was investigated
Figure 1 Appearance of right breast following radiotherapy.
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BRCA1 and BRCA2 genes by unidirectional DNA sequencing and
MLPA did not detect any mutations.
Patient A-T213 walked into the clinic unaided and unsupported.
There was no ataxia and tandem gait, feeding and swallowing were
normal. There was no oculomotor apraxia, no hypometric
saccades, no pursuit abnormalities and end gaze-evoked nystag-
mus but there was mild right esotropia. The patient showed no
adventitious movements. Finger–nose coordination showed some
end dysmetria and there was diminished vibration sense and joint
position sense up to knees, confirmed by EMG (mild axonal
polyneuropathy) and absent ankle and knee reflexes bilaterally.
Cellular radiosensitivity
Cultured skin fibroblasts from patient A-T213 showed increased
radiosensitivity by colony-forming assay, but were not as sensitive
as cells from a classical A-T patient (Figure 2). Similarly,
examination of chromosomal radiosensitivity of blood from
patient A-T213 showed a similar level of IR-induced damage that
was B3  more than the control, but less than ‘classical’ A-T
patients (A-T1 and A-T2, Table 1). Finally, following exposure to
IR, the patient’s fibroblasts showed a similar number of ATM-
dependent MDC1, gH2AX, 53BP1 and BRCA1 foci to the normal
control, although they were noticeably less bright (Supplementary
Figure 1). All these end points indicate some retained ATM
function in cells from patient A-T213.
ATM mutation analysis
Two ATM mutations, c.8672G4A. (p.Gly2891Asp) and c.1A4G
(Figure 3), were identified in the cells from patient A-T213 by DNA
sequencing the exons and exon/intron boundaries of the ATM
gene. Alterations were confirmed by sequencing cDNA derived
from the LCLs of patient A-T213. Sequencing of the parental ATM
genes confirmed that one mutation was carried on each allele of
chromosome 11, the c.8672G4A mutation was paternal and the
c.1A4G mutation maternal in origin.
The mutations are located in unusual positions, and both could
theoretically result in expression of mutant ATM protein. The
c.1A4G affects the first base in the coding sequence and might be
expected to ablate the initiation of ATM protein translation
altogether. However, mutation of the initiation codon AUG to GUG
could potentially result in the expression of ATM protein if the
GUG in the RNA was able to allow translation. The c.8672G4A
(p.Gly2891Asp) is a missense mutation located in the first base of
exon 60 (NM_000051.3) in the kinase domain. It was expected that
at the cDNA level the c.8672G4A mutation might result in loss of
exon 60. However, this was not the case and, therefore, this
mutation could also potentially result in the expression of mutant
ATM protein. Expression of mutant ATM protein with some
residual kinase activity from either one or both mutations could
contribute to the milder clinical and cellular phenotype of patient
A-T213.
Cellular ATM protein expression and kinase activity
The LCL of patient A-T213 expressed ATM protein, although the
level was reduced compared with a normal LCL (Figure 4). Both
A-T213 LCL (Figure 4A) and skin fibroblast lysates (Figure 4B
and C) showed residual ATM kinase activity. Therefore, both
kinase assays in vivo confirmed the presence of ATM with kinase
activity in the patient’s cells. In order to estimate the level of ATM
kinase activity, we performed an in vitro ATM kinase assay. The
ATM protein immunoprecipitated from A-T213 LCL lysate showed
greatly reduced activity towards a p53 substrate after DNA damage
(B12% of normal) (Figure 5A and B).
Finally, using LCL lysates we compared the ATM kinase
activities of cells derived from patient A-T213 with cells from
another breast cancer patient who was diagnosed with A-T
following a severe reaction to radiotherapy (A-T109, c.7271T4G
homozygous) (Stankovic et al, 1998). Although the level of ATM
expression was highest in the c.7271T4G cells, the level of kinase
activity appeared to be slightly greater in cells from patient A-T213
(Supplementary Figure 2).
Size and activity of the mutant ATM proteins
Immunoprecipitation of ATM from an LCL derived from patient
A-T86, carrying the initiating codon mutation, c.2T4C, on one
allele and a null mutation on the second allele, revealed an ATM
protein expressed at a lower level and slightly lower molecular
weight (Figure 5, lanes 7 and 8) than ATM wt protein (Figure 5,
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Figure 2 Colony-forming assay following exposure of cells to
137Cs
g-rays. The proportion (%) of surviving colonies was plotted against dose
of g-rays for normal TERT-immortalised cells, TERT-immortalised skin
fibroblasts from patient A-T213 and TERT-immortalised fibroblasts from
a classical A-T patient A-T1BR. The assay was repeated at least three times
for each cell strain. Error bars show the s.e.m. survival at each dose.
Table 1 Chromosome damage scored following exposure of a 72-h
blood culture to 1Gy
137Cs g-rays 4h before harvest
Patient
No. of
mitoses
analysed
No. of
tg
No. of
tb
No. of
trirad
No. of
quad
A-T213 sample 1 50 21 1 0 1
A-T213 sample 2 50 25 4 0 0
A-T1 50 118 38 5 4
A-T2 50 74 20 1 2
Control 50 8 0 0 0
Abbreviations: tg¼chromatid gaps; tb¼chromatid breaks; trirad¼triradial chromo-
somes; quad¼quadriradial chromosomes. A-T1 and A-T2 are classical ataxia
telangiectasia (A-T) patients.
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slanes 1 and 2). The slightly lower molecular weight ATM is
consistent with initiation of translation from a downstream AUG
codon resulting in a truncated protein. In translational terms the
c.1A4G mutation in A-T213 would be expected to behave like the
c.2T4C mutation as both mutations are in the initiation codon,
and would be expected to compromise its function. This would
result in the c1A4G mutation giving a similar truncated protein to
the c2T4C mutation.
The level of ATM protein immunoprecipitated from the LCL
from patient A-T213 (Figure 5, lanes 5 and 6) was greater than that
immunoprecipitated from cells from the c.2T4C patient A-T86
(Figure 5, lanes 7 and 8) but less than from normal cells (Figure 5,
lanes 1 and 2). Assuming that the c.1A4G and c.2T4C mutant
alleles result in a similar level of ATM, it is likely that most of the
ATM protein in cells from patient A-T213 came from the
c.8672G4A (p.Gly2891Asp) allele. Truncated ATM associated
Time (h) after IR
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Figure 4 ATM from A-T213 LCL and fibroblast lysates shows some retained ATM kinase activity. (A) A-T213 LCL lysate (lanes 3 and 4) shows the
presence of some ATM kinase activity towards the ATM targets Smc1, KAP1, Nbs1 and CREB after exposure to IR, but this is reduced compared with lysate
from a normal LCL (lanes 1 and 2). LCL lysate from a classical A-T patient A-T236, which does not express ATM, is shown in lanes 5 and 6. (B and C) Time
course of phosphorylation of different ATM downstream targets by A-T213 fibroblast ATM protein, showing the presence of kinase activity at 1h compared
with the classical A-T patient (A-T248) but reduced activity compared with normal ATM (normal 2).
Normal AB
Intron 59
Intron 59
Exon 60
Exon 60
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A-T 213 A-T 213 8672G>A 1A>G
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Figure 3 Electropherograms of mutations in genomic DNA in A-T213. Top panels show the wt sequence from a normal individual and the lower panels
the mutations at these positions in patient A-T213; (A) the c.1A4G mutation, and (B) the c.8672G4A mutation. The boxed sequence triplet in
(A) indicates the translation initiation codon.
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swith the presence of the c.1A4G mutation was not detected,
probably because it was obscured by the full-length ATM from the
c.8672G4A (p.Gly2891Asp) allele (Figure 5, compare lanes 5 and 6
and lanes 7 and 8). Consistent with this assertion was the finding
that the ATM protein expressed from the c.2T4C mutant allele in
the LCL from patient A-T187 could not be discriminated from
protein expressed from the second allele that was essentially full-
length p.Arg3047X (c.9139C4T) (Figure 5, lanes 9 and 10).
Interestingly, the level of ATM kinase activity in A-T213 was
clearly greater than that of ATM immunoprecipitated from A-T
cells carrying the mutation c.2T4C, which did not demonstrate
any in vitro kinase activity (Figure 5A and B). This suggests that
the ATM kinase activity in cells of patient A-T213 is from the
c.8672G4A (p.Gly2891Asp) allele.
In order to determine whether one or both mutant alleles
expressed ATM with some kinase activity, each mutation was
modelled separately by site-directed mutagenesis of full-length
normal ATM cDNA. Both the mutant protein associated with the
c.1A4G and the p.Gly2891Asp mutant protein are shown in
Figure 6A. Interestingly, the c.1A4G protein was of lower
molecular weight than wt ATM consistent with the use of a
downstream methionine for initiation. In contrast to the level of
ATM present in a normal LCL, the levels of both mutant proteins
were low, although expression of the p.Gly2891Asp mutant protein
was significantly higher than the c.1A4G protein (Figure 6A, lanes
4 and 5). We were unable to measure the level of ATM kinase
activity in either mutant protein because the levels of expression
were too low. However, it was possible to analyse ATM kinase
activity in the higher level of p.Gly2891Asp produced when it was
expressed with N-terminal tags (Figure 6B). The p.Gly2891Asp
mutant protein was autophosphorylated on ser1981 and was able
to phosphorylate the ATM targets Smc1, KAP1, Nbs1 and CREB
(Figure 6C, lane 6) after exposure to IR. The level of phosphoryla-
tion was greater than in cells with vector alone (Figure 6C, lane 4)
but substantially lower than in cells with ATM wt (Figure 6C, lanes
2 and 8).
Therefore, of the two possible expressed mutant ATM proteins
in A-T213, there was clear evidence that the p.Gly2891Asp mutant
protein was active. Consequently, the ATM kinase activity in the
cells of patient A-T213 was unlikely to be due to protein expressed
from the c.1A4G mutation. Indeed, the mutant c.1A4G ATM
cloned into pMEP4 was expressed as a lower molecular weight
protein consistent with the kinase-inactive truncated protein
expressed from the c.2T4C ATM mutant.
DISCUSSION
At the time of breast cancer diagnosis and until the end of
treatment, there was no clinical reason to suspect a diagnosis of
A-T in patient A-T213. Had it not been for the severe reaction to
radiotherapy, it is possible that the disorder would have remained
unrecognised as neurological features were minor. The A-T,
therefore, was very mild. However, fresh lymphocytes, an LCL and
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Figure 5 Full-length ATM is expressed in an LCL from patient A-T213,
and immunoprecipitated ATM from this LCL has kinase activity in vitro.
(A) Western blot (top and second panel; OE¼overexposed) showing
expression of ATM in a normal LCL (lanes 1 and 2), absence of ATM in
an LCL from a classical A-T patient (A-T183, lanes 3 and 4) and reduced
expression of ATM in LCL from A-T213 (lanes 5 and 6). Whereas the
ATM in patient A-T213 appears to be full length, the ATM in an LCL from
patient A-T86 with the c.2T4C mutation (and also null mutation
c.7665delinsGTGA;p.His2555Gln ins*) is slightly truncated (lanes 7 and 8).
It is likely that truncated ATM from c.2T4C in patient AT187 is obscured
by the p.Arg3047X (c.9139C4T) mutant protein (lanes 9 and 10) and
the truncated ATM from c.1A4G in patient A-T213 is obscured
by the p.Gly2891Asp (c.8672G4A) mutant protein (lanes 5 and 6).
Immunoprecipitated ATM was used to phosphorylate the p531–72
substrate in vitro
. (third and fourth panel) following activation of ATM by
IR. The level of normal radiation-induced ATM kinase activity is shown in
lane 2. There is absence of induced activity in cells from classical A-T patient
A-T183 (lane 4) with no ATM protein. Lane 6 shows induced activity of
ATM from the LCL of A-T213 but not from ATM of patient A-T86 with a
c.2T4C mutation and a second truncating mutation (lane 8) or from
patient A-T187 with a c.2T4C mutation and c.9139C4T (p.Arg3047X).
(B) Histogram of relative levels of ATM in vitro kinase activity from the
immunoprecipitates in Figure 5A.
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Figure 6 The p.Gly2891Asp protein has residual ATM kinase activity
and a higher level of expression than the protein expressed from the
c.1A4G mutation. (A) ATM protein without tags. ATM protein
expression after zinc induction in the LCL stably transfected with
pMEP4-ATM constructs was very low. Overexposure of the western blot
showed that the c.1A4G derived protein (1A4G, lane 4) is truncated and
accumulates to a lower level relative to the wt protein (pTAM2, lane 2) or
the p.Gly2891Asp protein (8672G4A, lane 5). No ATM protein was
expressed from the LCL transfected with vector alone (pMEP4, lane 3).
Aprataxin was used as a loading control. (B) ATM protein with N-terminal
tags. The induced levels of both wt protein (pTAM2, lane 2) and
p.Gly2891Asp protein (8672G4A, lane 4) were increased when the
ATM constructs were N-terminally tagged (compare with Supplementary
Figure 2A). The p.Gly2891Asp (8672G4A) protein was expressed at a
similar level to the wt protein. Aprataxin was used as a loading control.
(C) Comparison of ATM kinase activity in lysates from LCLs stably
transfected with pMEP4-ATM wt (pTAM2), pMEP4-ATM 8672G4A
(8672G4A) or pMEP4 vector alone (pMEP4) all with N-terminal tags.
Expression of the p.Gly2891Asp (8672G4A) protein (lane 5) was
comparable to that of wt ATM (pTAM2, lanes 1 and 7). The p.Gly2891Asp
(8672G4A) protein autophosphorylated Ser1981 following IR (lane 6) to
levels comparable to that of ATM wt protein (lanes 2 and 8). Levels of
IR-induced phosphorylation of ATM targets Smc1, KAP-1 and Nbs1 by the
p.Gly2891Asp (8672G4A) protein were substantially lower than those for
the ATM wt protein (lanes 2 and 8) but higher than for vector alone.
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sfibroblasts from the patient all showed a clearcut increased
radiosensitivity and defective focus formation of damage response
proteins, although not to the same extent as cells from a classical
A-T patient. In the context of this mild presentation, the two ATM
mutations, c.8672G4A (p.Gly2891Asp) and c.1A4G, in patient
A-T213 are both of considerable interest.
Interestingly, the c.8672G4A missense mutation was reported
in one of the breast cancer cases (but not in the controls) in the
study of Renwick et al (2006). Our study of this sequence change
now confirms this as a true ATM mutation, allowing a low level of
ATM expression with greatly reduced ATM kinase activity.
The ATM protein derived from the allele carrying the c.1A4G
mutation affecting the initiating methionine was truncated in the
same way as a protein derived from another mutation (c.2T4C) in
the same codon. Cells from a patient with the c.2T4C and an
ATM-null mutation expressed a truncated ATM protein with no
measurable ATM kinase activity. Therefore, it is unlikely that the
c.1A4G derived protein has any activity. In both cases, it is
possible that translation of transcripts may initiate at the second
or third in-frame AUG codons at codons 94 or 125, producing
an N-terminally truncated ATM protein. The smaller molecular
weight of ATM immunoprecipitated from both the c.2T4C mutant
cells and the modelled c.1A4G is consistent with this.
An alternative hypothesis is that initiation occurs at a down-
stream out-of-frame AUG and that the truncated ATM protein
expressed from the c.1A4G and c.2T4C mutant alleles is the
result of uncharacterised splicing events that restore the open
reading frame. There are five out-of-frame AUGs between the
primary AUG and the next in-frame AUG at codon 94. However,
none of them are in a good sequence context in comparison with
the optimal Kozak sequence, suggesting that they are unlikely to
function as translation-initiating codons. The most likely scenario,
therefore, is that the translation complex scans the mRNA until it
finds the in-frame AUGs at codons 94 or 125.
A number of studies have reported ATM mutation carriers to
have a 2–7-fold increased risk of breast cancer (Swift et al, 1991;
Easton, 1994; Athma et al, 1996; Stankovic et al, 1998; Inskip et al,
1999; Janin et al, 1999; Geoffroy-Perez et al, 2001; Olsen et al, 2001;
Bernstein et al, 2003; Thompson et al, 2005a,b; Reiman et al, 2011),
with increased risk presumably associated with loss of hetero-
zygosity, the sporadic loss of the normal ATM allele, resulting in
either total loss of or a large reduction in functional ATM protein.
Interestingly, this is the fourth time that neurologically milder A-T
has been diagnosed following radiotherapy for breast cancer
(Stankovic et al,1 9 9 8 ;F a n get al, 2010; Mandigers et al, 2011).
Stankovic et al (1998) reported a woman who experienced a severe
reaction of the breast and skin tissues after receiving adjuvant
radiotherapy following resection of her breast cancer. This woman
and two siblings, including a sister who also developed breast
cancer, were homozygous for the ATM mutation c.7271T4G
(p.Val2424Gly). The mutation was also identified in a second A-T
family where breast cancer occurred in carriers of the mutation. The
authors computed a relative risk of 12.7 associated with carrying
this ATM mutation, compared with a relative risk of 74.1 in
homozygotes, of developing breast cancer (Stankovic et al,1 9 9 8 ) .
Two other cases have been described. In the first case, a 50-year-
old breast cancer patient had a severe late adverse normal tissue
reaction to radiotherapy (Fang et al, 2010). Nucleotide sequence
analysis identified two nonallelic mutations in novel premature
termination mutation (c.1918A4T (Lys640Stop)) and a (c.1066-
6T4G (IVS10-6T-G)), which has previously been reported in A-T
patients (Austen et al, 2008). Although not described as an A-T
patient, this must be a strong possibility. In the second case, a
42-year-old breast cancer patient showed extreme radiosensitivity
in response to adjuvant radiotherapy following mastectomy
(Mandigers et al, 2011). Only one ATM mutation (c.8147T4C
(p.Val2716Ala)), which also has some ATM kinase activity
(Verhagen et al, 2009), was identified and the patient subsequently
diagnosed with A-T.
It is not known whether the ATM mutations in patient A-T213
were the cause of her breast cancer, although her relatively young
age and the absence of mutations in her BRCA1 and BRCA2 genes
would be consistent with this. With regard to potential mechanism
involving ATM, the presence of two mutant ATM proteins,
(p.Gly2891Asp and the c.1A4G derived protein) raises the
possibility of a dominant-negative effect of the inactive protein
on the active one. However, there is no evidence of a significant
effect of the inactive c.1A4G derived protein in reducing the
activity of the more abundant active p.Gly2891Asp protein, using
the levels of phosphorylation of ATM target proteins as a measure
of this potential effect. Although the mechanism of breast cancer
development is not known, it is possible that the overall level of
ATM kinase activity is below the threshold for tumour protection
and, indeed, any small dominant-negative effect of the inactive
protein could contribute to this. An alternative mechanism for the
development of breast cancer could be gain of function associated
with a mutant ATM protein; this could also apply to both the
p.Val2424Gly and the p.Val2716Ala ATM mutations.
The relationship between the clinical and cellular radiosensitiv-
ity in patient A-T213 is of some importance because despite not
having the more extreme cellular radiosensitivity of a ‘classical A-T
patient’, she clearly showed a severe clinical radiosensitivity. There
are insufficient data to relate the severity of the clinical end point
to that of the cellular end point, in terms of radiosensitivity. It is
not possible to determine whether the residual activity of ATM
protein expressed in her cells afforded her some degree of
protection against the worst possible effect of the irradiation dose
or, more generally, what is the threshold of cellular radiosensitivity
that will result in a clinically severe reaction to IR.
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